These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 19064381

  • 1. Postmarketing surveillance for oncology drugs.
    Viale PH, Moore S.
    Clin J Oncol Nurs; 2008 Dec; 12(6):877-86. PubMed ID: 19064381
    [Abstract] [Full Text] [Related]

  • 2. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL.
    J Clin Oncol; 2003 Oct 15; 21(20):3859-66. PubMed ID: 14551305
    [Abstract] [Full Text] [Related]

  • 3. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA, Brushwood DB.
    J Health Law; 2000 Oct 15; 33(3):383-454. PubMed ID: 11184355
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2008 Sep 29; 73(189):56487-91. PubMed ID: 18985960
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT.
    Food Drug Law J; 2007 Sep 29; 62(3):559-72. PubMed ID: 17915397
    [No Abstract] [Full Text] [Related]

  • 10. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR.
    Am Univ Law Rev; 2000 Sep 29; 49():739-72. PubMed ID: 11067732
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bolstering the FDA's drug-safety authority.
    Schultz WB.
    N Engl J Med; 2007 Nov 29; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS, Fischer MA, Avorn J.
    Health Aff (Millwood); 2006 Nov 29; 25(4):1095-102. PubMed ID: 16835191
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.